[go: up one dir, main page]

YU67402A - Nova upotreba (r)-(-)-2-/5-(4-fluorofenil)-3- piridilmetilaminometil/-hromana i njegovih fiziološki prihvatljivih soli - Google Patents

Nova upotreba (r)-(-)-2-/5-(4-fluorofenil)-3- piridilmetilaminometil/-hromana i njegovih fiziološki prihvatljivih soli

Info

Publication number
YU67402A
YU67402A YU67402A YUP67402A YU67402A YU 67402 A YU67402 A YU 67402A YU 67402 A YU67402 A YU 67402A YU P67402 A YUP67402 A YU P67402A YU 67402 A YU67402 A YU 67402A
Authority
YU
Yugoslavia
Prior art keywords
fluorophenyl
chromane
pyridylmethylaminomethyl
physiologically acceptable
acceptable salts
Prior art date
Application number
YU67402A
Other languages
English (en)
Inventor
Gerd Bartoszyk
Hermann Russ
Christoph Seyfried
Frank Weber
Original Assignee
Merck Patent Gmbh.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh. filed Critical Merck Patent Gmbh.
Publication of YU67402A publication Critical patent/YU67402A/sh
Publication of RS51316B publication Critical patent/RS51316B/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

(R)-(-)-2-[5-(4-fluorofenil)-3-piridilmetilaminometil]-hroman ili njegova fiziološki prihvatljiva so se upotrebljava za proizvodnju medikamenta za lečenje ekstrapiramidalnih poremećaja kretanja i/ili štetnih efekata kod ekstrapiramidalnih poremećaja kretanja. Pretpostavljena so je (R)-(-)-2-[5-(4-fluorofenil)-3-piridilmetilaminometil]-hroman hidrohlorid.[(R)-(-)-2-[5-(4-fluorophenyl)-3-ridylmethylaminomethyl]-chromane or a physiologically acceptable salt thereof is used for the manufacture of a medicament for the treatment of extrapyramidal movement disorders and/or adverse effects in extrapyramidal movement disorders. A preferred salt is (R)-(-)-2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane hydrochloride.
YUP-674/02A 2000-03-10 2001-02-01 Nova upotreba (r)-(-)-2-/5-(4-fluorofenil)-3- piridilmetilaminometil/-hromana i njegovih fiziološki prihvatljivih soli RS51316B (sr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP00104531 2000-03-10

Publications (2)

Publication Number Publication Date
YU67402A true YU67402A (sh) 2006-01-16
RS51316B RS51316B (sr) 2010-12-31

Family

ID=8168017

Country Status (29)

Country Link
US (1) US7928128B2 (sh)
EP (2) EP1645273A3 (sh)
JP (1) JP4901046B2 (sh)
KR (1) KR100830139B1 (sh)
CN (1) CN1188123C (sh)
AR (1) AR033807A1 (sh)
AT (1) ATE307578T1 (sh)
AU (2) AU2001230222C1 (sh)
BR (1) BR0109119A (sh)
CA (1) CA2402402C (sh)
CO (1) CO5271686A1 (sh)
CZ (1) CZ301807B6 (sh)
DE (1) DE60114419T2 (sh)
DK (1) DK1299099T3 (sh)
ES (1) ES2251460T3 (sh)
HK (1) HK1054198B (sh)
HU (1) HU229309B1 (sh)
ME (1) MEP5608A (sh)
MX (1) MXPA02008800A (sh)
MY (1) MY136976A (sh)
NO (1) NO329583B1 (sh)
PL (1) PL200781B1 (sh)
RS (1) RS51316B (sh)
RU (1) RU2278663C2 (sh)
SI (1) SI1299099T1 (sh)
SK (1) SK286933B6 (sh)
UA (1) UA73981C2 (sh)
WO (1) WO2001068063A2 (sh)
ZA (1) ZA200208133B (sh)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA73981C2 (en) 2000-03-10 2005-10-17 Merck Patent Gmbh (r)-(-)-2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane for treatment of extrapyramidal movement disorders (variants), pharmaceutical composition and kit
ATE352302T1 (de) * 2001-07-26 2007-02-15 Merck Patent Gmbh Verwendung von 2- 5-(4-fluorphenyl)-3- pyridylmethylaminomethyl-chroman und seiner physiologisch annehmbaren salze
DE60211186T2 (de) * 2001-09-19 2007-01-18 Merck Patent Gmbh Neue verwendung substituierter aminomethylchromane
BRPI0612752B8 (pt) * 2005-06-21 2021-05-25 Merck Patent Gmbh composição farmacêutica sólida compreendendo (r)-(-)-2-[5-(4-fluorfenil)-3-piridilmetilaminometil]cromano
US9066903B2 (en) 2006-02-28 2015-06-30 The United States Of America As Represented By The Department Of Veterans Affairs Pharmacological treatment of Parkinson's disease
US9248111B2 (en) * 2011-03-01 2016-02-02 Pharnext Therapeutic approaches for treating parkinson's disease
US10010515B2 (en) 2011-03-01 2018-07-03 Pharnext Therapeutic approaches for treating Parkinson's disease
CN108937972A (zh) * 2018-06-08 2018-12-07 青岛大学附属医院 一种多特征融合的就诊用户情绪监控方法

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2364685C3 (de) 1973-12-27 1978-06-15 Beiersdorf Ag, 2000 Hamburg Phenoxyäthylamine
US4438119A (en) * 1982-12-23 1984-03-20 Mead Johnson & Company Method for alleviation of extrapyramidal motor disorders
CA1337429C (en) 1983-12-05 1995-10-24 Guy Rosalia Eugene Van Lommen Derivatives of 2,2'-iminobisethanol
SE460947B (sv) * 1986-08-26 1989-12-11 Lejus Medical Ab En multiple-unit-dos komposition av l-dopa
DE3901814A1 (de) 1988-07-28 1990-02-01 Bayer Ag Substituierte aminomethylzetraline sowie ihre heterocyclischen analoga
EP0465254B1 (en) 1990-07-06 1996-11-13 Yoshitomi Pharmaceutical Industries, Ltd. Fused thiophene compounds and uses thereof
DE4135474A1 (de) 1991-10-28 1993-04-29 Bayer Ag 2-aminomethyl-chromane
US5314888A (en) 1992-02-21 1994-05-24 Trustees Of Tufts College Veterinary method for treating inappropriate elimination of urine in household pets
SI9300097B (en) 1992-02-27 2001-12-31 Janssen Pharmaceutica Nv (benzodioxan, benzofuran or benzopyran) alkylamino) alkyl substituted guanidines
AU3929493A (en) 1992-03-11 1993-10-05 Interneuron Pharmaceuticals, Inc. Reducing post-prandial fluctuations in plasma concentrations of large neutral amino acids (lnaa)
DE4226527A1 (de) 1992-08-11 1994-02-17 Merck Patent Gmbh 1,4-Benzodioxanderivate
JPH08503448A (ja) * 1992-12-07 1996-04-16 メレルダウファーマス−ティカルズ インコーポレイテッド ５ｈｔ▲下１▼▲ａ▼受容体アゴニストによる不随意運動の処置
GB9302622D0 (en) 1993-02-10 1993-03-24 Wellcome Found Heteroaromatic compounds
WO1995014006A1 (en) * 1993-11-19 1995-05-26 The Board Of Governors For Higher Education, State Of Rhode Island And Providence Plantations OCTAHYDROBENZO[f]QUINOLINE-BASED RECEPTOR AGONISTS AND ANTAGONISTS
CA2182101C (en) * 1994-01-31 1999-08-03 Todd W. Butler Neuroprotective compounds
IL114027A (en) 1994-06-08 1999-11-30 Lundbeck & Co As H 4-Phenyl piperazine (piperidine or tetrahydropyridine) derivatives serotinin 5-HT1A and dopamin D2 receptor ligand pharmaceutical compositions containing them
FR2723091B1 (fr) * 1994-07-29 1996-11-08 Esteve Labor Dr Tetrahydropyridine-(6,4-hydroxypiperidine) alkylazoles
DE69524528T2 (de) * 1994-10-14 2002-08-01 Merck Patent Gmbh ZNS wirksames (R)-(-)-2-[5-(4-Fluorophenyl)-3-pyridylmethylaminomethyl]chroman
US5502080A (en) * 1994-11-01 1996-03-26 Hitzig; Pietr Combined use of dopamine and serotonin agonists in the treatment of allergic disorders
US5554383A (en) 1995-04-06 1996-09-10 Trustees Of Tufts College Veterinary method for clinically modifying the behavior of dogs exhibiting canine affective aggression
US5541199A (en) * 1995-06-02 1996-07-30 American Home Products Corporation Chroman-2-ylmethylamino derivatives
AU6517196A (en) 1995-07-13 1997-02-10 Knoll Aktiengesellschaft Piperazine derivatives as therapeutic agents
GB9514380D0 (en) 1995-07-13 1995-09-13 Knoll Ag Therapeutic agents
US5670667A (en) 1995-07-25 1997-09-23 American Home Products Corporation Chroman-2-ylmethylamino derivatives
US5756521A (en) 1996-04-03 1998-05-26 American Home Products Corporation Chroman-2-ylmethylamino derivatives
DE19648384A1 (de) * 1996-11-22 1998-05-28 Merck Patent Gmbh Fluorene, Dibenzofurane und Dibenzothiophene
ATE253058T1 (de) 1997-09-02 2003-11-15 Duphar Int Res Piperidin- und piperazin derivate als 5-ht1- rezeptor-agonisten
EP0900792B1 (en) 1997-09-02 2003-10-29 Duphar International Research B.V Piperazine and piperidine derivatives as 5-HT1A and dopamine D2-receptor (ant)agonists
DE19751949A1 (de) 1997-11-24 1999-05-27 Bayer Ag Verwendung von substituierten Aminomethyl-Chromanen zur Verhinderung der neuronalen Degeneration und zur Förderung der neuronalen Regeneration
AU2981099A (en) 1998-03-09 1999-09-27 Trustees Of Tufts College Treatment of compulsive behaviours in man and animals
NZ506227A (en) * 1998-03-17 2003-06-30 Pfizer Prod Inc Bicyclo[2.2.1]heptanes and their use in treating neurological and psychiatric disorders
FR2781671A1 (fr) * 1998-07-28 2000-02-04 Synthelabo Compositions pharmaceutiques contenant un inhibiteur de la recapture de la serotonine et leur application en therapeutique
UA71590C2 (en) 1998-11-13 2004-12-15 Duphar Int Res Piperazine and piperidine derivatives
UA73981C2 (en) 2000-03-10 2005-10-17 Merck Patent Gmbh (r)-(-)-2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane for treatment of extrapyramidal movement disorders (variants), pharmaceutical composition and kit

Also Published As

Publication number Publication date
UA73981C2 (en) 2005-10-17
HUP0300079A2 (en) 2003-05-28
CO5271686A1 (es) 2003-04-30
CA2402402A1 (en) 2001-09-20
MY136976A (en) 2008-12-31
WO2001068063A3 (en) 2002-05-10
AU2001230222B2 (en) 2005-03-17
AU2001230222C1 (en) 2005-09-22
EP1645273A2 (en) 2006-04-12
MEP5608A (xx) 2010-02-10
CA2402402C (en) 2013-01-22
RU2002127006A (ru) 2004-03-27
EP1645273A3 (en) 2006-04-19
KR100830139B1 (ko) 2008-05-20
DE60114419T2 (de) 2006-07-27
HU229309B1 (en) 2013-10-28
WO2001068063A2 (en) 2001-09-20
ES2251460T3 (es) 2006-05-01
RS51316B (sr) 2010-12-31
ZA200208133B (en) 2004-04-01
CZ301807B6 (cs) 2010-06-30
DK1299099T3 (da) 2006-03-06
SK286933B6 (sk) 2009-07-06
AR033807A1 (es) 2004-01-07
EP1299099B1 (en) 2005-10-26
US7928128B2 (en) 2011-04-19
NO20024291L (no) 2002-09-09
RU2278663C2 (ru) 2006-06-27
AU3022201A (en) 2001-09-24
HK1054198B (zh) 2005-05-20
MXPA02008800A (es) 2003-02-12
NO329583B1 (no) 2010-11-15
SI1299099T1 (sl) 2006-04-30
CZ20022951A3 (cs) 2003-01-15
KR20030016236A (ko) 2003-02-26
US20030181486A1 (en) 2003-09-25
SK12642002A3 (sk) 2003-02-04
JP2004522692A (ja) 2004-07-29
JP4901046B2 (ja) 2012-03-21
CN1416344A (zh) 2003-05-07
NO20024291D0 (no) 2002-09-09
ATE307578T1 (de) 2005-11-15
PL356428A1 (en) 2004-06-28
DE60114419D1 (de) 2005-12-01
PL200781B1 (pl) 2009-02-27
HK1054198A1 (en) 2003-11-21
BR0109119A (pt) 2003-06-03
EP1299099A2 (en) 2003-04-09
CN1188123C (zh) 2005-02-09

Similar Documents

Publication Publication Date Title
GEP20074208B (en) Substituted amides active at the cannabinoid-1 receptor
GEP20053600B (en) 3-(4-Amidopyrrol-2-Ylmethlidene)-2- Indolinone Derivatives as Protein Kinase Inhibitors
GEP20074047B (en) Pramipexole once-daily dosage form
GB0005251D0 (en) Therapeutic compounds
IL165262A (en) Kinase inhibitors and pharmaceutical compositions containing them
IL152770A0 (en) Gabapentin analogues for sleep disorders
MXPA05003253A (es) Nuevos derivados de pirimidinamida y el uso de los mismos.
AP2003002929A0 (en) Pyrrolopyrimidines as protein kinase inhibitors
WO2002088100A3 (de) Deuterierte 3-piperidinopropiophenone sowie diese verbindungen enthaltende arzneimittel
CY1107616T1 (el) Καινοτομος χρηση της 2-[5-(4-φθοροφαινυλο)-3-πυριδυλομεθυλαμινομεθυλο]-χρωμανης και των φυσιολογικα αποδεκτων αλατων της
DK0981347T3 (da) Anvendelsen af levobupivacain i ansigtkirurgi
MEP5608A (xx) Nova upotreba (r) – (-)-2-[5-(4-fluorofenil)-3-piridil- metilaminometil] - hromana i njegovih fiziološko prihvatljivi h soli
EP1262197A3 (en) Combination treatment for sleep disorders including sleep apnea
MXPA03000439A (es) Nueva forma de (r)-n-(5-metil -8-(4-metilpiperazin -1-il) -1,2,3,4-tetrahidro-2-naftil) -4-morfolinobenzamida.
MY136449A (en) N-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide for the treatment of cancer
NZ535611A (en) Pharmaceutical composition of a PDE4 or a PDE3/4 inhibitor and a histamine receptor antagonist
MXPA02011533A (es) Nuevas formulaciones de alfa-2,4-disulfofenil-n-terc-butilnitrona.
HUP0402654A2 (hu) 2-[(2'-Halogén-3',5'-dialkoxi-fenil)-imino]-imidazolidin-származékok, alkalmazásuk és az ezeket tartalmazó gyógyszerkészítmények
GB0112494D0 (en) New therapeutic use
MXPA01009032A (es) Composicion farmaceutica para la prevencion o el tratamiento de una enfermedad asociada con un exceso se la produccion de il-12.
FR2802101B1 (fr) Association de cymemazine et d'un neuroleptique atypique
NO20010984D0 (no) Anvendelse av R(+)-<alfa>-(2,3-dimetoksyfenyl)-1-[2-(4- fluorfenyl)etyl]-4-piperidinmetanol for behandling av søvnforstyrrelser
FR2804867B1 (fr) Application de derives de xanthine pour la preparation d'un medicament destine a la prevention ou au traitement de l'osteoporose